Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2018-08-08 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
2018年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled '2018 年半年度报告' which translates to '2018 Semi-Annual Report'. It contains detailed financial data, including revenue, profit, cash flow, and segment analysis for the period January 1, 2018 to June 30, 2018. The content includes management discussion and analysis, business overview, financial metrics, and risk disclosures. The length is substantial (15,000 characters) and it contains actual financial statements and substantive financial data. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year. It is not an announcement or a certification, but the full report itself. Therefore, the correct classification is IR with high confidence. H1 2018
2018-08-08 Chinese
独立董事关于相关事项的独立意见
Audit Report / Information Classification · 90% confidence The document is an independent directors' opinion on several matters including related party transactions, external guarantees, use of raised funds, and appointment of senior management for the half-year period of 2018. It references compliance with regulatory guidelines and laws, and provides independent opinions rather than full financial statements or detailed financial data. The document length is short (1664 characters) and it is a formal opinion letter rather than a full interim or annual report. It does not contain comprehensive financial statements or substantive financial analysis. Therefore, it is not an Interim/Quarterly Report (IR) or Annual Report (10-K). It is also not a Management Report (MDA) because it is an independent directors' opinion. It is not a Regulatory Filing (RNS) because it is a formal independent opinion document. The best fit is Audit Report / Information (AR) as it contains independent directors' opinions on compliance and related party matters, which aligns with audit-related disclosures and opinions on governance and compliance matters. H1 2018
2018-08-08 Chinese
关于部分监事、高级管理人员股份减持计划时间过半的进展公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the progress of a share reduction plan by certain supervisors and senior management personnel of the company. It details the status of the planned share sales, compliance with relevant regulations, and confirms no shares have been sold yet. The document is short (1135 characters) and focuses on insider share transactions rather than financial results or corporate governance changes. It does not contain financial statements or detailed financial data. Therefore, it fits the category of a report on personal share transactions by company directors and executives, which corresponds to Director's Dealing (DIRS).
2018-08-01 Chinese
2018年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the 2018 first extraordinary shareholders' meeting of 特一药业集团股份有限公司. It details the meeting's convening method, attendance, voting results on a specific proposal regarding the downward adjustment of convertible bond conversion price, and legal opinions confirming the meeting's compliance with relevant laws. The document is a formal announcement of the voting results from a shareholders' meeting rather than the meeting materials or the full report itself. It is relatively short (2156 characters) and focuses on the voting outcomes and legal validation. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2018-07-27 Chinese
2018年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality of the convening, attendance, and voting procedures of a specific shareholders' meeting (the 2018 first extraordinary general meeting) of a company. It details the meeting's notice, attendance, voting methods, and results, and concludes on the legality of the meeting and its resolutions. It is not the actual voting results announcement itself, nor a proxy solicitation or a general regulatory filing. It is a legal opinion specifically about the shareholders' meeting. This type of document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to the official validation and announcement of voting results at a shareholders' meeting. The document length is under 5,000 characters, but it contains substantive legal opinion on the meeting's legality and voting results, not just a brief announcement or a report publication notice. Therefore, the best classification is DVA with high confidence.
2018-07-27 Chinese
关于“特一转债”转股价格向下修正的公告
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the downward adjustment of the conversion price of a convertible bond issued by the company. It details the previous and revised conversion prices, the date of implementation, and the rationale based on stock price performance and audited net asset value. There is no financial statement or comprehensive report included, only a specific corporate action announcement related to bond conversion terms. This fits the category of Capital/Financing Update (CAP), as it concerns changes in the company's capital structure and financing instruments.
2018-07-27 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.